Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. on September 26, 2016, reporting events occurring between August 30, 2016, and September 26, 2016. The filing details unregistered sales of equity securities and the entry into a material definitive agreement involving the company's director and principal stockholder.
Key Financial Metrics and Transactions
The filing reports specific capital raising and debt settlement activities rather than standard operating financial metrics such as revenue or net income.
- Director Investment: Sold 80,000 shares to John M. Desmarais at $3.00 per share, raising $240,000.
- Debt Settlement: Issued 24,390 shares to settle $26,315 in outstanding indebtedness (including accrued interest).
- Private Placements: Issued 25,000 shares at $3.00 per share ($75,000 total) and 11,000 shares at $2.73 per share ($30,030 total).
- Warrant Issuances: Granted five-year warrants for 80,000 shares (to Mr. Desmarais), 25,000 shares (to subscribers), and 11,000 shares (to a subscriber), all with an exercise price of $4.00 per share.
- Warrant Extensions: Extended existing warrants held by Mr. Desmarais for 444,444 and 400,000 shares by one year.
The filing text does not provide clear values for total revenue, profit, cash flow, margins, total debt, or liquidity positions.
Material Changes
The primary material change is the increase in outstanding common stock and warrant obligations resulting from the transactions listed above. The company settled a portion of its short-term indebtedness through equity conversion rather than cash payment.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of unregistered securities sales. The transactions relied on exemptions under Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933, noting that no general solicitation was used and investors were deemed accredited.
Investor Verification Checklist
- Verify the total number of outstanding shares and warrants post-transaction to assess dilution impact.
- Confirm the remaining balance of outstanding indebtedness after the $26,315 settlement.
- Review the terms of the extended warrants held by John M. Desmarais to understand future potential dilution.
- Check subsequent filings for the company's cash position following these capital raises.